tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Ravi Mehrotra, 14 are a BUY (100%).
Analyst Ravi Mehrotra, currently employed carries an average stock price target met ratio of 95% that have a potential upside of 28.49% achieved within 300 days.
Ravi Mehrotra’s has documented 27 price targets and ratings displayed on 2 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on BIIB, Biogen at 19-Mar-2015.
Analyst best performing recommendations are on BIIB (BIOGEN).
The best stock recommendation documented was for BIIB (BIOGEN) at 3/4/2013. The price target of $200 was fulfilled within 56 days with a profit of $43.45 (27.75%) receiving and performance score of 4.96.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$270
$96.21 (55.36%)
$270
5 days ago
(31-Oct-2024)
7/32 (21.88%)
$96 (55.17%)
255
Buy
$204
$30.21 (17.38%)
$436
5 days ago
(31-Oct-2024)
10/12 (83.33%)
$30 (17.24%)
62
Buy
$255
$81.21 (46.73%)
$270
5 days ago
(31-Oct-2024)
24/38 (63.16%)
$81 (46.55%)
326
Buy
$300
$126.21 (72.62%)
$300
5 days ago
(31-Oct-2024)
9/19 (47.37%)
$126 (72.41%)
260
Buy
$275
$101.21 (58.24%)
$305
5 days ago
(31-Oct-2024)
11/17 (64.71%)
$101 (58.05%)
162
What Year was the first public recommendation made by Ravi Mehrotra?
